New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia

Luca Laurenti, Simona Sica, Laura De Padua, Barbara Vannata, Idanna Innocenti, Michela Tarnani, Giuseppe Leone, G D'Arena, S Deaglio, Dg Efremov

Risultato della ricerca: Contributo in rivistaArticolo in rivista

2 Citazioni (Scopus)

Abstract

Over the last few years, several new agents have been under evaluation in preclinical studies and clinical trials, showing promise in treating chronic lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs) such as rituximab and alemtuzumab have changed the natural course of the disease. Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL.
Lingua originaleEnglish
pagine (da-a)508-518
Numero di pagine11
RivistaMINI-REVIEWS IN MEDICINAL CHEMISTRY
Volume11
Stato di pubblicazionePubblicato - 2011

Keywords

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, CD20
  • Antigens, CD40
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • Glycoproteins
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Receptors, IgE
  • Tetraspanins

Fingerprint Entra nei temi di ricerca di 'New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia'. Insieme formano una fingerprint unica.

Cita questo